Related Experiment Video
Updated: Oct 5, 2025
Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
Published on: June 7, 2020
Cerebral metastases
1Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway.
Abstract:
Brain metastases are common and deadly. Over the last 25 years GKNS has been established as an invaluable treatment. It may be used as a primary treatment or after either surgery or WBRT. Patients are assessed using one of a number of available scales. GKNS may be repeated for new metastases and for unresponsive tumors. Prescription doses are usually between 18 and 20Gy. The use of advanced MR techniques to highlight sensitive structures like the hippocampi have extended the efficacy of the treatment. More recently GKNS has been used with different target therapies with improved results. More recently frameless treatments have become more popular in this group of very sick patients. GKNS controls tumors in between 80% and over 95% of cases and may even be used for brainstem tumors.
Insights
Gamma Knife radiosurgery (GKNS) is a crucial treatment for brain metastases, offering high tumor control rates (80-95%). Advanced techniques and combination therapies enhance its efficacy, even for challenging cases like brainstem tumors.
Area of Science:
- Neurology
- Neurosurgery
- Radiation Oncology
Background:
- Brain metastases represent a significant clinical challenge, often associated with poor prognosis.
- Gamma Knife radiosurgery (GKNS) has been a cornerstone treatment for brain metastases for over two decades.
- GKNS offers a non-invasive therapeutic option, utilized as primary treatment or following surgery/whole brain radiation therapy (WBRT).
Purpose of the Study:
- To review the established role and evolving applications of GKNS in managing brain metastases.
- To highlight advancements in GKNS delivery and its integration with other therapeutic modalities.
- To underscore the efficacy and safety profile of GKNS in a diverse patient population.
Main Methods:
- Review of clinical data and treatment outcomes for patients with brain metastases treated with GKNS.
- Assessment of patient selection criteria and treatment planning using various clinical scales.
- Integration of advanced imaging techniques, such as MRI, for precise targeting and dose delivery.
Main Results:
- GKNS demonstrates high rates of tumor control, ranging from 80% to over 95%.
- The treatment can be repeated for recurrent or new metastases and unresponsive tumors.
- Advanced MR techniques and combination therapies with targeted agents have improved outcomes.
- Frameless GKNS approaches are increasingly adopted for critically ill patients.
Conclusions:
- GKNS is an effective and versatile treatment for brain metastases, including those in critical locations like the brainstem.
- Technological advancements and multimodal treatment strategies continue to enhance GKNS efficacy.
- GKNS remains an invaluable tool in the multidisciplinary management of brain metastases.
